Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
Alector (NASDAQ:ALEC – Free Report) had its price target reduced by HC Wainwright from $35.00 to $7.00 in a report published on Friday, MarketBeat.com reports. They currently have a buy rating on the ...
Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.
On Friday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.6 which represents a slight increase of $0.05 or 1.96% from the prior close of $2.55. The stock opened at $2.55 and ...
Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...
As of 12:34:05 PM EST. Market Open. Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
On Wednesday, Alector Inc (ALEC) stock saw a decline, ending the day at $2.55 which represents a decrease of $-0.02 or -0.78% from the prior close of $2.57. The stock opened at $2.6 and touched a low ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
And the first IPO without a fixed share price since the shutdown ended late last month was from Alector, a biotech that is aiming to find new treatments for dementia. Alector fell on its trading ...
The company is also running mid-stage trials of ABBV-552, an SV2A modulator, which is being evaluated to enhance synaptic efficiency in Alzheimer's, and Alector-partnered TREM2-directed antibody ...